DXVX (180400)

Overview

Dx & Vx Co., Ltd., headquartered in Seoul, South Korea, operates at the forefront of molecular diagnostics, spearheading the development and commercialization of innovative techniques for a variety of genetic diseases. Established in 2001 and initially known as Cancer Rop Co., Ltd., the company underwent a rebranding in January 2022 to better reflect its expanded focus beyond cancer diagnostics. Today, Dx & Vx is recognized for its pioneering work in enhancing the success rates of in vitro fertilization, prenatal and postnatal health assessments, and the precise diagnosis of genetic disorders in both children and adults. The company’s dedication to research and development has placed it at the cutting edge of diagnosing sexually transmitted infections, cervical cancer, and other significant health challenges through the creation of advanced diagnostic reagents and tools.

Products and Services

• BAC Chip Microarray

This gene-based microarray technology stands out as Dx & Vx's flagship innovation. It is engineered to detect both numerical and structural chromosomal abnormalities. With its broad range of applications, the BAC chip can improve the success rate of in vitro fertilization, facilitate fetal health checks, diagnose chromosomal abnormalities in children and adults presenting health concerns, aid in the detection of chromosomal aberrations in cancer cells, and verify the chromosomal integrity in stem cells.

• Reagents for Diagnostic Tools

In its relentless pursuit to tackle various diseases at the molecular level, Dx & Vx is actively engaged in the development of highly specialized reagents. These reagents are instrumental for diagnostic tools employed in the definitive diagnosis of cervical cancer, sexually transmitted infections (STIs), and an array of other diseases. The company's innovative approach aims to provide healthcare professionals with accurate, efficient, and accessible diagnostic solutions to facilitate timely and effective patient care.